These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35975761)

  • 1. New investigational agents for the treatment of major depressive disorder.
    Pochwat B; Krupa AJ; Siwek M; Szewczyk B
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
    Chaki S; Fukumoto K
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
    Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
    Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A
    Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
    du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
    Onisiforou A; Georgiou P; Zanos P
    Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
    Chaki S; Watanabe M
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1451-1462. PubMed ID: 36715750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
    Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
    Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacological innovation in the treatment of depression.
    Witkin JM; Golani LK; Smith JL
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):349-362. PubMed ID: 37000975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
    Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
    Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of serotonin neurotransmission in rapid antidepressant actions.
    Pehrson AL; Roberts D; Khawaja A; McNair R
    Psychopharmacology (Berl); 2022 Jun; 239(6):1823-1838. PubMed ID: 35333951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
    Dogra S; Conn PJ
    Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
    Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
    Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
    Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
    Musazzi L
    Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
    Johnston JN; Kadriu B; Allen J; Gilbert JR; Henter ID; Zarate CA
    Neuropharmacology; 2023 Mar; 226():109422. PubMed ID: 36646310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.